Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT06152523	TitleMonalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer	Phase Phase 2	Date Added 2023-11-30	Location France	Prior IO Allowed No	CRC-directed Yes	Status Not yet recruiting	Drugs Monalizumab/MEDI5257	Tags MSI-H/ MMRd
NCT ID NCT04444622	TitleImmunotherapy for Third Line Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2020-06-23	Location Florida, United States Michigan, United States New Jersey, United States New York, United States	Prior IO Allowed No	CRC-directed Yes	Status Completed	Drugs	Tags MSS/ MMRp
NCT ID NCT05879822	TitleA Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive	Phase Phase 2	Date Added 2023-05-30	Location Brazil China Georgia Greece Hungary New Zealand Romania South Africa Turkey	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs INCB099280	Tags MSI-H/ MMRd
NCT ID NCT05999812	TitleClinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer	Phase Phase 2	Date Added 2023-08-21	Location Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs all trans Retinoic Acid, Atezolizumab, Bevacizumab	Tags MSS/ MMRp
NCT ID NCT06006923	TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer	Phase Phase 2	Date Added 2023-08-23	Location California, United States Florida, United States Illinois, United States Michigan, United States Pennsylvania, United States Washington, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Pembrolizumab, Regorafenib, Keytruda, Stivarga	Tags MSI-H/ MMRd
NCT ID NCT06014502	TitleStudy to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors	Phase Phase 1	Date Added 2023-08-28	Location Arizona, United States California, United States Louisiana, United States Texas, United States	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs IMGS-001	Tags MSI-H/ MMRd
NCT ID NCT06176885	TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2023-12-20	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Camrelizumab	Tags MSS/ MMRp
NCT ID NCT06106308	TitleStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	Phase Phase 2	Date Added 2023-10-30	Location Arizona, United States Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Bevacizumab, FOLFIRI, FOLFOX, Onvansertib	Tags MSS/ MMRp
NCT ID NCT05286814	TitleM9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma	Phase Phase 2	Date Added 2022-03-18	Location Maryland, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSS/ MMRp

Showing 291 to 299 of 299 entries